Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

BACKGROUND: Tamoxifen, an endocrine therapy drug used to treat breast cancer, is designed to interrupt estrogen signaling by blocking the estrogen receptor (ER). However, many ER-positive patients are low reactive or resistant to tamoxifen. Metformin is a widely used anti-diabetic drug with notewort...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ji, Guo, Yan, Chen, Suning, Zhong, Cuiping, Xue, Yan, Zhang, Yuan, Lai, Xiaofeng, Wei, Yifang, Yu, Shentong, Zhang, Jian, Liu, Wenchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976359/
https://www.ncbi.nlm.nih.gov/pubmed/24612549
http://dx.doi.org/10.1186/1471-2407-14-172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976359/
https://www.ncbi.nlm.nih.gov/pubmed/24612549
http://dx.doi.org/10.1186/1471-2407-14-172

Ejemplares similares